Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 115.65B |
| Revenue (ttm) | 57.67B |
| Net Income (ttm) | 7.28B |
| Shares Out | n/a |
| EPS (ttm) | 1.28 |
| PE Ratio | 15.89 |
| Forward PE | 8.37 |
| Dividend | 1.55 (7.58%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 28,781 |
| Average Volume | 45,885 |
| Open | 20.27 |
| Previous Close | 20.14 |
| Day's Range | 20.15 - 20.44 |
| 52-Week Range | 18.57 - 28.75 |
| Beta | 0.50 |
| RSI | 40.15 |
| Earnings Date | Aug 5, 2025 |
About Activision Blizzard
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsNews
Final Trade: PFE, AFRM, LYFT, AEM
The final trades of the day with CNBCs Melissa Lee and the "Fast Money" traders.
Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason.
Pfizer’s strong EPS beat streak faces test as Q2 earnings loom
Pfizer (PFE) Q2 earnings preview: Analysts project modest growth, with EPS at $0.57 and revenue at $13.53B.
Earnings Outlook For Pfizer
Pfizer (NYSE: PFE) is set to give its latest quarterly earnings report on Tuesday, 2025-08-05. Here's what investors need to know before the announcement. Analysts estimate that Pfizer will report an...
Pfizer: Earnings Meet Pressure (Rating Upgrade)
How To Earn $500 A Month From Pfizer Stock Ahead Of Q2 Earnings
Pfizer Inc. PFE will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5.
The 3 Things That Matter for Pfizer Now
The sell-off of this pharmaceutical giant might be overdone.
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE:PFE) is set to announce its earnings on Tuesday, August 5, 2025, prior to the market opening. Analyzing Pfizer's stock performance over the previous five years after earnings announcement...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2159881840-e2e04c33a90644f9b7479e6e93e53199.jpg)
What To Expect in Markets This Week: Earnings From Palantir, AMD, McDonald’s and More
Also scheduled: Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE: NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleedin...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.This decision affirms the ...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo Nordisk.